Pharmaceutical group “Saidal” intends to start the production of anti-cancer drugs as a complete process, with Korean partner “CKD OTTO”, within 2023, according to a press release issued by the Ministry of Pharmaceutical Industry today, Tuesday.
The press release indicated that “with a gradual merger, the Algerian-Korean partnership in the field of oncology production, as a first stage, will begin with secondary packaging and conditioning, before passing to production as a complete process and to the production of the raw material by 2023.”
This will allow Saidal “to play a role in covering the needs of materials intended for oncology, which are experiencing regular disruptions in abundance, and will also allow it to contribute to the health sovereignty of the country and constitute a support for economic growth,” according to the ministry, which confirmed that this project is “the first of its kind in Algeria in terms of raw material production.
On this occasion, the Minister of Pharmaceutical Industry Djamel Lotfi Benbahmed affirmed “the full support provided by the Algerian authorities for the realization of this partnership project, which is beneficial to both parties, as well as their support in order to be able to achieve the established goals within the specified deadlines, in order to respond to the country’s health priorities and economic growth.”
ENTV 24/11/2021
